Highlight
Endogenous glucose-dependent insulinotropic polypeptide (GIP) significantly contributes to the postprandial increase in splanchnic blood flow among individuals with type 2 diabetes. Infusion of a GIP receptor antagonist leads to a measurable reduction in mesenteric arterial blood flow and attenuates insulin secretion without affecting plasma glucose levels. This randomized, placebo-controlled, crossover study provides important insights into vascular and endocrine regulation during glucose metabolism in this population.
